Clinical studies of FK037 on complicated urinary tract infection

Keizo Suzuki; Masaki Horiba; Shinobu Katoh; Masahiro Yonezu; Kiyohito Ishikawa; Yorio Naide; Masanori Yanaoka; Shinichi Ando

doi:10.11250/chemotherapy1953.42.Supplement3_448

Clinical studies of FK037 on complicated urinary tract infection

Keizo Suzuki
, Masaki Horiba
, Shinobu Katoh
, Masahiro Yonezu
, Kiyohito Ishikawa
, Yorio Naide
, Masanori Yanaoka
, Shinichi Ando

Research output: Contribution to journal › Article › peer-review

Abstract

FK037, a new injectable cephem antibiotic, was administered in the treatment of 14 complicated urinary tract infections. The drug was given at doses of 0.25~1.0g b. i. d. by intravenous drip infusion for 5 days. The clinical efficacy was evaluated as excellent or moderate in 11 cases out of 13, 85% by the Japanese UTI criteria. Bacteriologically, 20 strains out of 22, 91% were eradicated after the therapy. Against strains of Pseudomonas aeruginosa, the response was 1 out of 3 strains. In the safety profile, no side events or abnormal laboratory findings were caused by FK037.

Original language	English
Pages (from-to)	448-453
Number of pages	6
Journal	CHEMOTHERAPY
Volume	42
DOIs	https://doi.org/10.11250/chemotherapy1953.42.Supplement3_448
Publication status	Published - 1994
Externally published	Yes

All Science Journal Classification (ASJC) codes

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.42.Supplement3_448

Cite this

@article{c49e2463a41c4ad88662c2a8b2f81235,

title = "Clinical studies of FK037 on complicated urinary tract infection",

abstract = "FK037, a new injectable cephem antibiotic, was administered in the treatment of 14 complicated urinary tract infections. The drug was given at doses of 0.25\textasciitilde{}1.0g b. i. d. by intravenous drip infusion for 5 days. The clinical efficacy was evaluated as excellent or moderate in 11 cases out of 13, 85\% by the Japanese UTI criteria. Bacteriologically, 20 strains out of 22, 91\% were eradicated after the therapy. Against strains of Pseudomonas aeruginosa, the response was 1 out of 3 strains. In the safety profile, no side events or abnormal laboratory findings were caused by FK037.",

author = "Keizo Suzuki and Masaki Horiba and Shinobu Katoh and Masahiro Yonezu and Kiyohito Ishikawa and Yorio Naide and Masanori Yanaoka and Shinichi Ando",

year = "1994",

doi = "10.11250/chemotherapy1953.42.Supplement3\_448",

language = "English",

volume = "42",

pages = "448--453",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

}

TY - JOUR

T1 - Clinical studies of FK037 on complicated urinary tract infection

AU - Suzuki, Keizo

AU - Horiba, Masaki

AU - Katoh, Shinobu

AU - Yonezu, Masahiro

AU - Ishikawa, Kiyohito

AU - Naide, Yorio

AU - Yanaoka, Masanori

AU - Ando, Shinichi

PY - 1994

Y1 - 1994

N2 - FK037, a new injectable cephem antibiotic, was administered in the treatment of 14 complicated urinary tract infections. The drug was given at doses of 0.25~1.0g b. i. d. by intravenous drip infusion for 5 days. The clinical efficacy was evaluated as excellent or moderate in 11 cases out of 13, 85% by the Japanese UTI criteria. Bacteriologically, 20 strains out of 22, 91% were eradicated after the therapy. Against strains of Pseudomonas aeruginosa, the response was 1 out of 3 strains. In the safety profile, no side events or abnormal laboratory findings were caused by FK037.

AB - FK037, a new injectable cephem antibiotic, was administered in the treatment of 14 complicated urinary tract infections. The drug was given at doses of 0.25~1.0g b. i. d. by intravenous drip infusion for 5 days. The clinical efficacy was evaluated as excellent or moderate in 11 cases out of 13, 85% by the Japanese UTI criteria. Bacteriologically, 20 strains out of 22, 91% were eradicated after the therapy. Against strains of Pseudomonas aeruginosa, the response was 1 out of 3 strains. In the safety profile, no side events or abnormal laboratory findings were caused by FK037.

UR - https://www.scopus.com/pages/publications/0028116045

UR - https://www.scopus.com/pages/publications/0028116045#tab=citedBy

U2 - 10.11250/chemotherapy1953.42.Supplement3_448

DO - 10.11250/chemotherapy1953.42.Supplement3_448

M3 - Article

AN - SCOPUS:0028116045

SN - 0009-3165

VL - 42

SP - 448

EP - 453

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

ER -

Clinical studies of FK037 on complicated urinary tract infection

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this